Title:Inhibiting Monoamine Oxidase in CNS and CVS would be a Promising Approach to Mitigating Cardiovascular Complications in Neurodegenerative Disorders
Volume: 23
Issue: 3
Author(s): Princika Srivastava, Sachithra Thazhathuveedu Sudevan, Arumugam Thennavan, Bijo Mathew*S.K. Kanthlal*
Affiliation:
- Department of Pharmaceutical Chemistry, Amrita School of Pharmacy,
Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, 682 041, India
- Department of Pharmacology, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Science
Campus, Kochi, 682 041, Kerala, India
Keywords:
Monoamine oxidases, cardiovascular system (CVS), mitochondrial outer membrane, neurodegenerative, neural patients, AD, PD.
Abstract: The flavoenzyme monoamine oxidases (MAOs) are present in the mitochondrial outer
membrane and are responsible for the metabolism of biogenic amines. MAO deamination of biological
amines produces toxic byproducts such as amines, aldehydes, and hydrogen peroxide, which are significant
in the pathophysiology of multiple neurodegenerative illnesses. In the cardiovascular system
(CVS), these by-products target the mitochondria of cardiac cells leading to their dysfunction and producing
redox imbalance in the endothelium of the blood vessels. This brings up the biological relationship
between the susceptibility of getting cardiovascular disorders in neural patients. In the current
scenario, MAO inhibitors are highly recommended by physicians worldwide for the therapy and management
of various neurodegenerative disorders. Many interventional studies reveal the benefit of
MAO inhibitors in CVS. Drug candidates who can target both the central and peripheral MAO could
be a better to compensate for the cardiovascular comorbidities observed in neurodegenerative patients.